These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 7975756)

  • 21. Enhancing effect of HT008-1 on cognitive function and quality of life in cognitively declined healthy adults: a randomized, double-blind, placebo-controlled, trial.
    Kim J; Chung SY; Park S; Park JH; Byun S; Hwang M; Oh DS; Choi H; Kim MY; Bu YC; Doré S; Whang WW; Kim H
    Pharmacol Biochem Behav; 2008 Oct; 90(4):517-24. PubMed ID: 18550156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network.
    Kornhuber J; Schmidtke K; Frolich L; Perneczky R; Wolf S; Hampel H; Jessen F; Heuser I; Peters O; Weih M; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Pantel J; Rienhoff O; Seuchter SA; Rüther E; Henn F; Maier W; Wiltfang J
    Dement Geriatr Cogn Disord; 2009; 27(5):404-17. PubMed ID: 19339779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [When should the brain imaging be done in suspected dementia?].
    Soininen H; Sulkava R
    Duodecim; 2000; 116(10):1037-8. PubMed ID: 11989014
    [No Abstract]   [Full Text] [Related]  

  • 24. [Nootropic drugs and their action mechanisms in relation to the neuropathobiology of senile dementia. I. Neurotransmission disorders in the brain].
    Benesová O
    Cesk Psychiatr; 1994 Aug; 90(4):191-200. PubMed ID: 7987928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A hormonal drug melatonin in the treatment of cognitive function disorders in parkinsonism].
    Arushanian EB
    Eksp Klin Farmakol; 2010 Mar; 73(3):35-9. PubMed ID: 20408429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Alzheimer drugs for mild cognitive impairment].
    Fellgiebel A
    Neuropsychiatr; 2007; 21(3):230-3. PubMed ID: 17915184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Nootropic drug evaluation for general practice].
    Ihl R; Kretschmar C
    Nervenarzt; 1997 Nov; 68(11):853-61. PubMed ID: 9732727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Electrophysiological evaluation of the demented state and the nootropic effect of TA-0910 by "automated fluctuation analysis" of the high-frequency EEG--relation between neuropsychological test results and Lorentzian parameters].
    Nakata M
    No To Shinkei; 1996 Jun; 48(6):551-8. PubMed ID: 8703558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Dementias: mostly clinico-neuropsychological or mostly psychometric diagnosis?].
    Spinnler H
    Ann Ist Super Sanita; 2005; 41(1):75-80. PubMed ID: 16037654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Ginkgo Biloba as a cognitive enhancer].
    Arushanian EB; Beĭer EV
    Eksp Klin Farmakol; 2008; 71(4):57-63. PubMed ID: 18819443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nootropics: pharmacological properties and therapeutic use.
    Gabryel B; Trzeciak HI
    Pol J Pharmacol; 1994; 46(5):383-94. PubMed ID: 7894524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dementia.
    Warner J; Butler R
    Clin Evid; 2002 Jun; (7):846-66. PubMed ID: 12230710
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors.
    Rozzini L; Costardi D; Chilovi BV; Franzoni S; Trabucchi M; Padovani A
    Int J Geriatr Psychiatry; 2007 Apr; 22(4):356-60. PubMed ID: 17117398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dementia.
    Warner J; Butler R; Jackson E
    Clin Evid; 2002 Dec; (8):927-50. PubMed ID: 12603921
    [No Abstract]   [Full Text] [Related]  

  • 35. [Ginkgo extract in people with declining mental performance].
    Kaschel R
    Pharm Unserer Zeit; 2009; 38(5):432-9. PubMed ID: 19711319
    [No Abstract]   [Full Text] [Related]  

  • 36. [Effect pf anti-dementia drugs on the daily routine and attitude of dementia patients].
    Kurz A
    Z Gerontol Geriatr; 1999 Jun; 32(3):167-71. PubMed ID: 10436496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ethical issues in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Post SG; Beerman B; Brodaty H; Gaines AW; Gauthier SG; Geldmacher DS; Hill S; Homma A; Rossor MN; Whitehouse PJ; Winblad B
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():26-8. PubMed ID: 9305511
    [No Abstract]   [Full Text] [Related]  

  • 38. Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity.
    Nehl C; Paulsen JS;
    J Nerv Ment Dis; 2004 Jan; 192(1):72-4. PubMed ID: 14718780
    [No Abstract]   [Full Text] [Related]  

  • 39. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.
    Aarsland D; Hutchinson M; Larsen JP
    Int J Geriatr Psychiatry; 2003 Oct; 18(10):937-41. PubMed ID: 14533126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term changes in ADAS-cog: what is clinically relevant for disease modifying trials in Alzheimer?
    Vellas B; Andrieu S; Cantet C; Dartigues JF; Gauthier S
    J Nutr Health Aging; 2007; 11(4):338-41. PubMed ID: 17653494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.